February 27, 2015

OmniPod's & Artificial Pancreas

OmniPod's CEO spoke of artificial pancreas in Q&A at the most recent earnings call:
Patrick Sullivan - President & CEO
Yes, I would say our strategy is that as it relates to the artificial pancreas, we are putting together strategy so that OmniPod is a very significant part of the artificial pancreas product offering in the future. And with that you need to have a CGM product offering, as well as an offering to put the three units together if you will, and as you know we have been working internally on our own CGM development which continues but also we have an agreement with - already have an agreement with Dexcom to use their CGM sensor along with our new PDM to integrate that those two products together, and I think with that combination used in algorithm and we're looking at opportunities to have an algorithm that we could then provide the full package. I'd also say that we would evaluate and look at opportunities with Abbott and others that would have potential CGM integration opportunities for us. So in the short term we're looking at other people that have CGM capabilities and algorithm capability, but at the same time we are continuing at a low level our own efforts in our own CGM product development.


  1. Following up with Insulet on their CGM R&D and path toward an AP, I posed a few questions and this is what I've received as a response:

    “Insulet is committed to advancing diabetes care and as part of that advancement we intend to ensure that our patients have real-time access to their blood glucose levels. To that end, we are pursuing multiple options including a continued partnership with DexCom, as well as other potential partnership opportunities. As such, we have multiple R&D initiatives underway. While we have many exciting projects in development now and with the recent senior management changes we are actively looking at ways to expedite our efforts while also seeking ways to provide additional, clinically meaningful enhancements to our patients and health care providers. To directly answer your questions:

    Insulet is not developing a CGM censor on our own.
    Yes (Insulet is continuing to work with a partner on developing a CGM sensor)
    At this time we are not disclosing that partner.
    The only changes since 2013 are that we are looking at more CGM partners and finding new ways to work together towards a goal of a closed-loop system.

    Thought you'd be interested to hear that.